Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 1, 2011

Sigma-Aldrich Takes Over Resource Technology to Expand Analytical Suite

Sigma-Aldrich Takes Over Resource Technology to Expand Analytical Suite

Acquisition follows about a month after Cerilliant purchase.[frenta-Fotolia.com]

  • Sigma-Aldrich acquired the assets of Resource Technology (RTC) of Laramie, WY. The deal is expected to complement the recent acquisition of Cerilliant and strengthen Sigma-Aldrich’s analytical chemistry offerings.

    The RTC product offerings also complement the company’s Supelco and Fluka brand analytical reagents, standards, and separation consumables. RTC adds expertise in design, development, characterization, and packaging of analytical standards, matrix standards, certified reference materials, and proficiency testing.

    The RTC campus is situated on 4.5 acres spread between three buildings. The new building provides an additional 21,600 sq. ft. of space.

    “The strong and innovative products offered by RTC bring new opportunities for expanding our business,” remarks Russel Gant, vp of the analytical research business for Sigma-Aldrich. “Their experienced team, capabilities, and customer contacts combine nicely with our breadth of products, high-quality portfolio, extensive scientific knowledge, and global footprint.”

    This is the second acquisition made by Sigma-Aldrich in the past month or so. In December 2010, the company picked up Cerilliant, a supplier of reference standards and materials that support the clinical diagnostics, clinical toxicology, environmental, forensic, nutraceutical, and pharmaceutical markets.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »